Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Insulin tolerance test Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

NCT04958109
View directory record Official record
Conditions
Metabolic Diseases
Interventions
Oral Glucose Tolerance Test, Kisspeptin, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alpelisib in Healthy Volunteers

NCT05733455
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions
Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage
Drug · Device · Diagnostic Test + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Not applicable Interventional

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

NCT00015691
View directory record Official record
Conditions
HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions
Metformin hydrochloride, Rosiglitazone maleate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 20, 2026, 3:58 PM EDT
Recruiting No phase listed Observational

Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes

NCT07650682
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Dependent Diabetes
Interventions
Not listed
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 3:58 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Alpelisib Challenge Test (ACT)

NCT07778524
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions
Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp
Drug · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 20, 2026, 3:58 PM EDT
Completed No phase listed Observational Results available

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

NCT01099397
View directory record Official record
Conditions
Prediabetic State
Interventions
Oral glucose tolerance test
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Not applicable Interventional Results available

Impact of Inflammation on Reward Circuits, Motivational Deficits and Negative Symptoms in Schizophrenia

NCT03818516
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Glucose Tolerance Test (OGTT)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 59 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 20, 2026, 3:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

NCT02282423
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies
Behavioral · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 59 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 20, 2026, 3:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular and Metabolic Responses to a Mixed Meal

NCT00882986
View directory record Official record
Conditions
Insulin Resistance
Interventions
Not listed
Lead sponsor
John Thyfault
Other
Eligibility
20 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 20, 2026, 3:58 PM EDT
Not listed No phase listed Observational

Body Composition Assessment in Spinal Cord Injury

NCT00957762
View directory record Official record
Conditions
Diabetes Mellitus, Body Composition, Tetraplegia, Paraplegia, Spinal Cord Injury
Interventions
Body composition
Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2009 · Synced Oct 20, 2026, 3:58 PM EDT
Completed No phase listed Observational

Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus

NCT02346344
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Not listed
Lead sponsor
Foundation for the National Institutes of Health
Other
Eligibility
30 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Tempe, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2015 · Synced Oct 20, 2026, 3:58 PM EDT
Withdrawn Phase 4 Interventional

Regression of Fatty Heart by Valsartan Therapy

NCT00745953
View directory record Official record
Conditions
Metabolic Syndrome, Lipotoxicity
Interventions
Valsartan, Hydrochlorothiazide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)

NCT00004984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Parenteral Insulin, Close Observation, Oral Insulin, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
3 Years to 45 Years
Enrollment
711 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 2003
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

NCT00283816
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
Drug · Behavioral · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2015 · Synced Oct 20, 2026, 3:58 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy

NCT01951716
View directory record Official record
Conditions
Does the Vagus Nerve Mediate the Effects of Xenin-25
Interventions
Graded Glucose Infusion with Placebo, Graded Glucose Infusion with GIP Alone, Graded Glucose Infusion with xenin-25 alone, Graded Glucose Infusion with GIP plus xenin-25, Meal Tolerance Test with Placebo, Meal Tolerance Test with xenin-25
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 20, 2026, 3:58 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

NCT07494084
View directory record Official record
Conditions
Shift Work Schedule, Circadian Rhythm, Insulin Resistance, Circadian Misalignment
Interventions
Metyrapone And Hydrocortisone, Dextrose, insulin
Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 3:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Glycemic Index of Commonly Consumed Sweeteners

NCT02931578
View directory record Official record
Conditions
Healthy
Interventions
Glucose100, Glucose50, Glucose42, Oral Glucose Tolerance Test
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 20, 2026, 3:58 PM EDT
Terminated Not applicable Interventional

Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)

NCT02052479
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS
Interventions
Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 20, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional

Mechanisms of Ultrasound Neuromodulation Effects in Diabetes

NCT06042517
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
Ultrasound, OGTT with unlabeled glucose and liver NMR, OGTT with carbon-13 labeled glucose and liver NMR, CGM glucose reading, HEC - Hyperinsulinemic-Euglycemic-Clamp
Device · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes

NCT01633177
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Vitamin D3, Omega-3 fatty acid (fish oil), Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
22,220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 20, 2026, 3:58 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacogenomics of GLP1 Receptor Agonists

NCT05762744
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 20, 2026, 3:58 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes, Type 2 Diabetes, Pre Diabetes
Interventions
Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

NCT02871882
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obese, Overweight
Interventions
Gastric Emptying test, Mixed Oral Glucose Tolerance test, Conjugated bile acids sodium, Placebo
Radiation · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional

US Inhaled Insulin Dose Titration Study

NCT00246623
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Exubera (inhaled insulin), 8-point glucose diary (to assess pre- and post prandial glucoses), Meal Tolerance Test, 24-hour continuous glucose monitoring (at select sites), Pulmonary Function Testing, Hypoglycemic Event Monitoring, Laboratory Assessments, Nutritional Counseling and Diabetes Education
Drug · Procedure · Behavioral
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2008 · Synced Oct 20, 2026, 3:58 PM EDT